January 20, 2021 -- Akron Biotech and Octapharma have signed an exclusive agreement to produce virally inactivated human AB serum to bring it to the cell therapy market.
Akron will produce human AB serum converted from Octapharma's pooled solvent/detergent treated human plasma product. Together, they aim to enhance the safety of human serum from viruses, such as SARS-CoV-2.
The products will be colabeled and available in the U.S., E.U., and Asia.